ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly
Authors:
Open Access
- 30 November 2023
- journal article
- editorial
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (2)
Abstract
This article summarises a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the International Congress of the European Respiratory Society in 2023. Translational and clinical studies focused on the whole spectrum of ILDs, from (ultra)rare ILDs to sarcoidosis, ILDs associated with connective tissue disease and idiopathic pulmonary fibrosis. The main topics of the 2023 Congress presentations were improving the diagnostic process of ILDs, better prediction of disease course and investigation of novel treatment options.Keywords
This publication has 52 references indexed in Scilit:
- Development and validation of a nomogram for predicting pulmonary complications after curative resection in idiopathic pulmonary fibrosis patients with early stage lung cancerEuropean Respiratory Journal, 2023
- Electronic nose technology differentiates interstitial lung diseases from other chronic respiratory diseasesEuropean Respiratory Journal, 2023
- Buccal microbiome and survival in idiopathic pulmonary fibrosis: CleanUP-IPFEuropean Respiratory Journal, 2023
- Late Breaking Abstract - A KIF15 missense variant is associated with a distinct prognostic clinical phenotype in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2023
- Experience of making early interstitial lung disease diagnosis from patients taking part in UK national pilot lung screening programme.2023
- Late Breaking Abstract - Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF study (NCT04396756)European Respiratory Journal, 2023
- Nationwide All ILD registry with central MDD in Japan; Providing Multidisciplinary ILD diagnoses (PROMISE) study.European Respiratory Journal, 2023
- The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study.European Respiratory Journal, 2023
- High-dose (40 mg)versuslow-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)European Respiratory Journal, 2023
- ERS International Congress 2021: highlights from the Interstitial Lung Diseases AssemblyERJ Open Research, 2022